Lasa Supergenerics has commenced the trial production at Unit IV, situated at Chiplun in state of Maharashtra. The Unit IV was earlier known as Unit V. The regular production will be subject to success of the trial runs. The company is geared up to take advantage of this significant opportunity and expand in lines with strategic plans.
The planned production and capacity per annum includes Albendazole Intermediate (400 MT), Fenbendazole Intermediate (200 MT), 2 4 DCP (600 MT), Closantel Intermediate (100 MT) and additionally a few components of backward integration for its recent new launches.
Lasa Supergenerics manufactures and distributes chemicals. The company offers veterinary API products, animal feed ingredients, and reagents for therapeutic uses.
